BioActor Overview
- Founded
- 2011

- Status
- Private
- Employees
- 16

- Latest Deal Type
- 2ndary - Private
- Investors
- 2
BioActor General Information
Description
Developer of natural health ingredients designed to promote healthy living and general well-being. The company's ingredients are natural, innovative, clinically proven, and produced in Europe and are used in dietary supplements, medical nutrition, and functional foods, enabling consumers to stay fit in the face of health concerns related to metabolic syndrome and aging such as diabetes, osteoporosis, and cardiovascular disease as well as in cases of excess cholesterol, blood pressure, and bone-related issues.
Contact Information
- Maastricht Health Campus
- Gaetano Martinolaan 50
- 6229 GS Maastricht
- Netherlands
BioActor Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
2. Secondary Transaction - Private | 01-Mar-2021 | 00.000 | Completed | Clinical Trials - Phase 1 | ||
1. Early Stage VC | 25-Jul-2011 | 00.000 | 00.000 | Completed | Clinical Trials - Phase 1 |
BioActor Comparisons
Industry
0000000
000000
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialBioActor Competitors (2)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Fytexia | Formerly PE-Backed | Vendres, France | 00 | 000000&0 | ||
000000 | Formerly PE-Backed | Rouen, France | 000 | 00000000000 |
BioActor Patents
BioActor Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
EP-3431093-A1 | Wheat-derived polysaccharides for reduction of antibiotic resistance | Withdrawn | 17-Jul-2017 | 0000000000 | 0 |
EP-3585378-A1 | Flavanones for use in treating visceral hypersensitivity | Pending | 24-Feb-2017 | 0000000000 | |
US-11141420-B2 | Flavanones for use in treating visceral hypersensitivity | Active | 24-Feb-2017 | 0000000000 | 00 |
US-20200230165-A1 | Flavanones for use in treating visceral hypersensitivity | Granted | 24-Feb-2017 | 0000000000 | |
US-20200030400-A1 | Aronia extract for enhancing reaction time and attention | Granted | 10-Feb-2017 | A61K36/73 |
BioActor Executive Team (3)
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Hans van der Saag | Founder & Chief Executive Officer | ||
Bob Gutjahr | Chief Sales Officer | ||
Yala Stevens | Chief Scientific Officer & Head Clinical Research |
BioActor Board Members (1)
Name | Representing | Role | Since |
---|---|---|---|
Peter Van Gelderen Ph.D | Icos Capital | Board Member | 000 0000 |
BioActor Signals
Growth Rate

Growth

Size Multiple


Key Data Points
Twitter Followers
5.5k

Similarweb Unique Visitors
15.0K

Majestic Referring Domains
314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialBioActor Investors (2)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Brightlands Venture Partners | Venture Capital | Minority | 000 0000 | 000000 0 | |
Icos Capital | Venture Capital | Minority | 000 0000 | 000000 0 |